Shu-Han Liu

Cancer degronopathies and protein-fate biomarkers in drug resistance and cancer progression: signalling mechanisms, measurement and translational limits

Drug resistance remains a major barrier to durable targeted therapy, and cancer progression often reflects rewiring of signalling pathways that control protein stability. Dysregulation of the ubiquitin–proteasome system, including failure of degron-dependent substrate recognition, can stabilise oncogenic proteins, acce...